New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.
Hadj Tahar
A
A
Unité de Recherche en Neuroscience, Centre de Recherche du CHUQ, Institut Universitaire de Gériatrie de Montreal, Montreal, Quebec, Canada.
Grondin
R
R
Grégoire
L
L
Calon
F
F
Di Paolo
T
T
Bédard
P J
PJ
D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D006801:Humans; D007980:Levodopa / Q000009:adverse effects*; D009434:Neural Pathways / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D011954:Receptors, Dopamine / Q000187:drug effects / Q000378:metabolism
D011954:Receptors, Dopamine; D007980:Levodopa; D004298:Dopamine